Johnson & Johnson (LTS:0R34) FFO


LTS:0R34 Johnson & Johnson LTS:0R34
87 GF Score
Price $265.77
GF Value $189.93
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Johnson & Johnson FFO?

FFO (Funds from operations) only applies to REITs.

LTS:0R34
87GF Score
Johnson & Johnson LTS:0R34
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Johnson & Johnson (LTS:0R34) Overvalued in 2026?

Based on GuruFocus' analysis, Johnson & Johnson stock appears to be overvalued. The current stock price of $265.77 is trading 39.9% above its estimated GF Value™ of $189.93. GuruFocus considers Johnson & Johnson to be Significantly Overvalued.

Key valuation signals for LTS:0R34:

  • FFO:
  • GF Value™: $189.93 vs. price of $265.77 (39.9% above fair value)
  • GF Score™: 87/100 with 7 warning signs

No single metric tells the full story. See the LTS:0R34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Johnson & Johnson Business Description

Address One Johnson & Johnson Plaza, New Brunswick, NJ, USA, 08933
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.
87GF Score

Get the complete analysis for LTS:0R34

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$265.77
Price
$189.93
GF Value